Topics

Therapeutic Targets for Metabolic Dysfunction-Associated Fatty Liver Disease

Metabolic Diseases Diabetes Chronic Inflammation Mitochondrial Dysfunction

Metabolic dysfunction-associated fatty liver disease (MAFLD) reframed fatty liver disease around metabolic dysfunction rather than exclusion of alcohol or other liver disorders. The 2020 international expert consensus defined MAFLD by hepatic steatosis plus overweight/obesity, type 2 diabetes mellitus, or evidence of metabolic dysregulation, establishing positive diagnostic criteria and emphasizing disease severity rather than a simple steatohepatitis/non-steatohepatitis dichotomy. This conceptual shift builds on decades of research into fatty liver as a continuum from steatosis to steatohepatitis, fibrosis, cirrhosis, and liver cancer, while connecting liver pathology directly with diabetes and metabolic syndrome. The resulting disease framework has intensified interest in mechanism-based drug discovery because the heterogeneous biology creates multiple potentially actionable metabolic, inflammatory, and fibrogenic targets[1][2].

Therapeutic targeting follows the interconnected mechanisms that sustain hepatic lipid accumulation, cellular injury, inflammation, and fibrosis. Resmetirom targets thyroid hormone receptor-β (THR-β); in a phase 3 trial, this liver-directed agonist produced significantly greater steatohepatitis resolution and at least one-stage fibrosis improvement than placebo, while also reducing low-density lipoprotein cholesterol. GLP-1 receptor signaling represents another metabolic axis: semaglutide produced significantly more NASH resolution than placebo in a phase 2 trial, although improvement in fibrosis stage did not differ significantly between groups. Peroxisome proliferator-activated receptors integrate metabolic, inflammatory, and fibrogenic regulation; the pan-PPAR agonist lanifibranor improved the SAF activity score and favored NASH resolution and fibrosis improvement.

These approaches illustrate how therapeutic intervention can address upstream metabolic dysfunction while simultaneously influencing downstream hepatic injury. FGF21 signaling adds a complementary endocrine strategy directed at metabolic homeostasis and fibrotic disease. Pegozafermin, a long-acting FGF21 analogue, produced fibrosis improvement in patients with biopsy-confirmed noncirrhotic NASH and F2-F3 fibrosis, supporting continued development of the FGF21 pathway. Together with THR-β, GLP-1R, and PPAR modulation, these findings show that drug discovery increasingly spans hepatic lipid metabolism, systemic metabolic control, inflammatory activity, and extracellular-matrix remodeling rather than relying on a single pathogenic node[2][3][4][5].

The clinical examples also reveal important differences among targets: semaglutide strongly affected steatohepatitis resolution without significant fibrosis improvement in its phase 2 study, whereas resmetirom, lanifibranor, and pegozafermin generated signals involving fibrosis endpoints. Such differences make target selection particularly relevant to disease stage and therapeutic objective. Major gaps remain because MAFLD is biologically heterogeneous and therapeutic effects on metabolic activity, steatohepatitis, and fibrosis do not necessarily occur together. The major trials cited here used histological surrogate endpoints over relatively short treatment periods, leaving longer-term effects on progression, cirrhosis, and other clinical outcomes to be established[3][4][5][6].

Adverse effects also differ among mechanisms: gastrointestinal events occurred more frequently with resmetirom and semaglutide, lanifibranor was associated with diarrhea, nausea, peripheral edema, anemia, and weight gain, and nausea and diarrhea were common with pegozafermin. Future research therefore needs mechanism-informed patient stratification, durable assessment of fibrosis and clinical outcomes, and rational combination strategies that address complementary metabolic, inflammatory, and fibrogenic pathways. The diversity of successful target classes supports a precision-therapy model in which treatment selection reflects the dominant biological drivers and stage of liver disease[2][3][4][5][6].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L084 Microbial Metabolite Library
Nature has been a source of medicinal products for millennia, with many useful active substances developed from plant sources. In the 20th century, the discovery of the penicillin was the starting point for drug discovery from microbial sources. Microorganisms， which have been considered to be a rich source of unique bioactive compounds, play an important role in the development of the chemistry of natural products and medical therapy. Microbial metabolites have proved to be affective antimicrobial agents, anti-tumor agents, enzyme inhibitors, anti-inflammatory agents, etc. Today, many microbial-originated antibiotics are available in the mark, and a large number of bioactive metabolites are used in medicine. MCE provides a unique collection of 939 microbial metabolites, which is an important source of lead compounds and can be used for drug discovery.

Metabolism Focused Libraries Natural Product Screening Libraries

87
HY-L109 Protein-protein Interaction Inhibitor Library
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 826 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Signaling Pathway Targeting Libraries

86
HY-L147 Protease Inhibitor Library
A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. Proteases play important roles in regulating multiple biological processes in all living organisms, such as regulating the fate, localization, and activity of many proteins, modulating protein-protein interactions, creating new bioactive molecules, contributing to the processing of cellular information, and generating, transducing, and amplifying molecular signals. Proteases are important targets in drug discovery. Some protease inhibitors are often used as anti-virus drugs and anti-cancer drugs. MCE offers a unique collection of 956 protease inhibitors. MCE Protease Inhibitor Library is critical for drug discovery and development.

Signaling Pathway Targeting Libraries

86
HY-L078 Gut Microbial Metabolite Library
Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods. In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 475 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

Metabolism Focused Libraries

85
HY-L091 Lipid Metabolism Compound Library
Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation. MCE offers a unique collection of 1,026 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

Signaling Pathway Targeting Libraries

85
HY-L013 Neuronal Signaling Compound Library
Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders. MCE designs a unique collection of 3,961 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Signaling Pathway Targeting Libraries

84
HY-L040 Anti-diabetic Compound Library
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 1,172 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Disease Focused Libraries

84
HY-L053 NMPA-Approved Drug Library
From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc. MCE provides a unique collection of 1,534 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

Drug Repurposing Series

84
HY-L060 Cytoskeleton Compound Library
The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases. MCE designs a unique collection of 2,313 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

Signaling Pathway Targeting Libraries

84
HY-L069 Anti-Alzheimer's Disease Compound Library
Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc. MCE offers a unique collection of 2,174 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

Disease Focused Libraries

84
HY-L182 Fatty Acids Compound Library
Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases. MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Structure Classified Libraries

84
HY-L0086V Specs HTS Compounds Library
A unique collection contains 200,382 diverse chemical compounds to pharmaceutical and biotechnology scientists for drug discovery.
83
HY-L0113V 1M Drug Fragment-Based Diversity Library
A diversity compound library contains 1,000,000 compounds with drug fragments. Each compound has at least one drug fragment. These selected molecules have 702,902 Bemis-Murcko Scaffolds (BMS) with drug-like chemical space. This library is highly recommended for AI-based lead discovery, ultra-large virtual screening and novel lead discovery.
83
HY-L021M Natural Product and Natural Product-Like Compound Library
From the discovery of traditional Chinese medicine to modern antibiotics, natural products have played an important role in the drug development process. A review of all FDA-approved drugs shows that natural products and natural product-like compounds account for more than one-third of all approved drugs. Nearly half of that came from mammals, a quarter from microbes, and a quarter from plants. Over time, the proportion of microbial natural products and natural product derivatives in approved drugs has increased. Natural products have natural advantages in drug development and can be used as lead compounds in drug discovery for drug identification and mechanism research. MCE provides a unique collection of 20,566 natural compounds and natural product-like compounds that contain saccharides and glycosides, phenylpropanoids, quinones, flavonoids, terpenoids and glycosides, steroids, alkaloid, phenols, acids and aldehydes. Natural product and natural product-like compounds library is a useful tool for drug discovery that can be used for high-throughput screening (HTS) and high-content screening (HCS).
83
HY-L041 Macrocyclic Compound Library
Macrocycles, molecules containing 12-membered or larger rings, are receiving increased attention in small-molecule drug discovery. The reasons are several, including providing access to novel chemical space, challenging new protein targets, showing favorable ADME- and PK-properties. Macrocycles have demonstrated repeated success when addressing targets that have proved to be highly challenging for standard small-molecule drug discovery, especially in modulating macromolecular processes such as protein–protein interactions (PPI). Otherwise, the size and complexity of macrocyclic compounds make possible to ensure numerous and spatially distributed binding interactions, thereby increasing both binding affinity and selectivity. MCE offers a unique collection of 468 macrocyclic compounds which can be used for drug discovery for high throughput screening (HTS) and high content screening (HCS). MCE Macrocyclic Compound Library is a useful tool for discovering new drugs, especially for “undruggable” targets and protein–protein interactions.

Structure Classified Libraries

83
HY-L064 Glutamine Metabolism Compound Library
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 1,827 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Signaling Pathway Targeting Libraries

83
HY-L087 Anti-Obesity Compound Library
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,741 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Disease Focused Libraries

83
HY-L090 Transcription Factor-Targeted Library
Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential. MCE offers a unique collection of 2,569 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.

Signaling Pathway Targeting Libraries

83
HY-L108 Antidepressant Compound Library
Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors. Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent. MCE offers a unique collection of 3,059 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

Disease Focused Libraries

83
HY-L137 Molecular Glue Compound Library
Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention. Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy. MCE supplies a unique collection of 124 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

Compound Characteristic Classified Libraries

83
HY-L138 Heterocyclic Compound Library
Heterocyclic compounds are cyclic organic compounds which contain at least one hetero atom, the most common heteroatoms are nitrogen, oxygen ,and sulfur. Heterocycles are common in biology, featuring a wide range of structures from enzyme co-factors to amino acids and proteins. On the one hand, heterocycles are common structural units in approved drugs and in medicinal chemistry targets in the drug discovery process. In addition, heterocycles have been found as a key structure in medical chemistry and also they are frequently found in large percent of biomolecules such as vitamins, natural products ,and biologically active compounds including antifungal, anti-inflammatory, antibacterial, antioxidant, antiallergic, anti-HIV, antidiabetic, anticancer activity. MCE offers a unique collection of 6,553 heterocyclic compounds which can be used for drug discovery for high throughput screening (HTS) and high content screening (HCS). MCE heterocyclic compound library is critical for drug discovery and development.

Structure Classified Libraries

83
HY-L177 Antibody Inhibitor Library
Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases. MCE can provide 1,949 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Compound Characteristic Classified Libraries

83
HY-L185 Anti-Fibrosis Compound Library
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 2,568 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Disease Focused Libraries

83
HY-L199 Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 5,024 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.
83
HY-L208 Bile Acids Library
Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases. MCE included 62 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.
83
HY-L217 Mouse Metabolite Compound Library
Metabolic abnormalities lead to dysfunction of metabolic pathways and the accumulation or lack of metabolites, which are recognized hallmarks of the disease. The metabolite signature is closely related to the disease phenotype and is very useful for predicting the diagnosis and prognosis of the disease as well as monitoring treatment. Metabolites can be used as disease markers for diagnostic therapy. As the classic model of disease experiment in vivo, mice metabolites also play a role in disease diagnosis and mechanism research. MCE provides 330 mouse metabolites that can be used in disease research.

Metabolism Focused Libraries

83
HY-L227 Amino Acid Metabolite Compound Library
Amino acids are the fundamental components that sustain life activities, playing roles in ATP generation, promoting nucleotide synthesis, and maintaining cellular redox balance. Moreover, dysregulation of amino acid consumption is a significant potential regulatory mechanism leading to impaired anti-tumor immunity in immune cells. The normal functioning of immune cells relies on amino acid metabolic pathways to obtain energy and materials, and upon activation, they reprogram their metabolism to support growth, proliferation, and effector functions. Additionally, metabolic disorders of specific amino acids (such as branched-chain amino acids, glutamine, and arginine) can exacerbate mitochondrial dysfunction and oxidative stress, thereby promoting myocardial fibrosis and cardiac cell damage. Therefore, conducting research related to amino acid metabolism holds promise for discovering potential drugs for diseases related to cancer, immunity, and metabolism. MCE can provide 195 kinds of metabolites of amino acid metabolic pathways, which can be used for drug screening in various diseases such as cancer, immune disorders, metabolic diseases, mitochondrial-targeted diseases

Metabolism Focused Libraries

83
HY-L228 Lipid Metabolite Compound Library
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health. One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses. MCE can offer 146 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.

Metabolism Focused Libraries

83
HY-L236 Amine Fragment Library
Fragment-based drug discovery (FBDD) offers a strategic advantage by categorizing fragment hits according to their functional groups. This approach facilitates both the further optimization of these hits and the rational design of larger compounds through fragment combination. The amine functional group plays a vital role in drug development, as evidenced by its presence in many marketed drugs like Galantamine, Tacrine, and Rivastigmine. It is instrumental in enhancing solubility, improving bioavailability, and ensuring shelf-life stability—all critical factors for drug efficacy. MCE offers a collection of 20,065 amine fragments for drug discovery. All of these compounds adhere to the Rule of Three (RO3) criteria for drug-likeness, which MCE offers a collection of 20,065 amine fragments for drug discovery, all of which stipulates a molecular weight ≤ 300 Da, ≤ 3 hydrogen bond donors, ≤ 3 hydrogen bond acceptors, and a cLogP ≤ 3.
83
HY-L252 Carbohydrate Metabolite Compound Library
Carbohydrate metabolism serves as a central hub for energy supply and biosynthesis in living organisms and plays a critical role in the onset and progression of various diseases. In recent years, studies have shown that tumor cells reprogram their energy metabolism through aerobic glycolysis (the Warburg effect) to support rapid proliferation. Immune cells also rely on specific carbohydrate metabolic pathways to regulate their activation and differentiation states, while disorders such as diabetes and metabolic syndrome arise directly from dysregulation of carbohydrate metabolism. In addition, enzymes and key metabolic nodes involved in carbohydrate metabolism have become important targets for drug discovery, and therapeutic strategies targeting glycolysis, the pentose phosphate pathway, and energy metabolism are continuously advancing the treatment of cancer and metabolic diseases. Therefore, systematic analysis of carbohydrate metabolic networks and their associated metabolites is of great significance for elucidating disease mechanisms and developing novel therapeutic approaches. The MCE Carbohydrate Metabolism Metabolite Library is constructed based on classical carbohydrate metabolic pathways and contains 76 metabolites. It systematically integrates key metabolic networks, including glycolysis, the pentose phosphate pathway, the tricarboxylic acid (TCA) cycle, monosaccharide metabolism, and sugar acid interconversions. The library comprehensively covers core metabolic nodes from glucose uptake and utilization to energy production and biosynthesis, while also incorporating important upstream and downstream intermediates. It enables accurate representation of intracellular metabolic flux dynamics and is well suited for applications such as metabolic flux analysis, target validation, and mechanistic studies. Furthermore, it provides robust support for multi-omics integration and the development of precision intervention strategies.
83
HY-L263 Energy Metabolites Library
Energy metabolism is the most fundamental biochemical process in living organisms, encompassing glycolysis, the TCA cycle, oxidative phosphorylation, the pentose phosphate pathway, and fatty acid oxidation. These core pathways directly regulate cell survival, proliferation, differentiation, and apoptosis. Dysregulation of energy metabolism is closely linked to major diseases including cancer, diabetes, obesity, cardiovascular diseases, neurodegenerative disorders, and ischemia‑reperfusion injury. Targeting these metabolic pathways has become a frontier in drug discovery and mechanistic research. The MCE Energy Metabolite Compound Library features 89 structurally defined small‑molecule compounds. It covers energy substrates, pathway intermediates, coenzymes and redox carriers, nucleotide derivatives, and microenvironmental modulators. This library is applicable to research areas including tumor metabolism, insulin resistance, mitochondrial dysfunction, oxidative stress, neuroprotection, and cardiometabolic diseases, providing a high‑quality tool for mechanistic studies, biomarker discovery, and high‑throughput drug screening.

Signaling Pathway Targeting Libraries

83
HY-L265 Cholesterol Metabolism Compound Library
Cholesterol is a crucial lipid that maintains cell membrane structure, serves as a precursor for the synthesis of steroid hormones and bile acids, and plays an important role in cell signal transduction and membrane function regulation. Intracellular cholesterol levels are precisely controlled by multiple processes, including synthesis, uptake, transport, esterification, storage, and efflux. Dysregulation of cholesterol metabolism is closely associated with diseases such as atherosclerosis, fatty liver disease, metabolic syndrome, and various cancers. The Cholesterol Metabolism Compound Library contains 558 compounds and focuses on cholesterol metabolism and homeostatic regulation. It provides an efficient tool for mechanistic studies of cholesterol metabolism and for drug discovery in metabolism‑related diseases.
83
HY-L926 Cysteine Protease Focused Covalent Library
Cysteine proteases (CPs), a key enzyme family regulating physiological metabolism and mediating pathological processes (e.g., abnormal bone resorption, tumour invasion, and pathogen infection), represent a core therapeutic target for disease intervention via the development of specific inhibitors. Currently reported CP covalent inhibitors encompass diverse structural types, including epoxides, aziridine, and activated double bonds (vinyl sulphones, α,β-unsaturated ketones), providing clear structural references for the development of novel CP covalent inhibitors. This compound library contains multiple warheads that specifically target cysteine proteases, serving as a powerful tool for the efficient discovery of novel covalent inhibitors against this enzyme family.

Focused and target libraries

83
HY-L927 10K Golden Scaffold Library
Designed to maximize efficiency in hit discovery and optimization, this compound library is built on a foundation of diverse Bemis-Murcko scaffolds, with each scaffold is represented by two specifically derived molecules. This strategy ensures broad chemical space through scaffold diversity while enabling preliminary functional group exploration. This approach provides early structure-activity relationship (SAR) insights for every scaffold, making it a valuable tool for accelerating drug discovery.

Distinctive Diversity Libraries

83
HY-B0445A NAD sodium
NAD sodium is an orally effective cofactor and homeostatic regulator. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions that oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria, which indirectly generates ATP. NAD sodium can be used for the research of non-alcoholic fatty liver disease, obesity, and glucose intolerance.
Endogenous Metabolite  
Glucose Metabolism  
53
HY-114118C Semaglutide sodium
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118B Semaglutide acetate
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118A Semaglutide TFA
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118 Semaglutide
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-A0070 Liothyronine sodium
Liothyronine sodium is an active form of thyroid hormone. Liothyronine sodium is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively.
Thyroid Hormone Receptor   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
46
HY-A0070A Liothyronine
Liothyronine is an active form of thyroid hormone. Liothyronine binds to thyroid hormone receptors TRα and TRβ with Kis of 2.33 and 2.29 nM for hTRα and hTRβ, respectively. Liothyronine also binds to PVR and blocks the interaction of TIGIT/PVR.
Thyroid Hormone Receptor   Endogenous Metabolite  
Metabolic or Endocrine Disease  
46
HY-P0014 Liraglutide
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
GCGR   GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease   Parkinson's Disease   Type 1 Diabetes   Psoriasis   Chronic Obstructive Pulmonary Disease   Type 2 Diabetes   Obesity  
43
HY-W087947 EDTA dihydrate tripotassium
EDTA dihydrate tripotassium (Ethylenediaminetetraacetic acid dihydrate tripotassium) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA dihydrate tripotassium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA dihydrate tripotassium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA dihydrate tripotassium can alleviate the liver fibrosis. EDTA dihydrate tripotassium can be used for coronary artery disease and neural system disease research.
Bacterial   SOD  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
29
HY-W105700 Ethylenediaminetetraacetic acid sodium hydrate
Ethylenediaminetetraacetic acid (EDTA) sodium hydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid sodium hydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid sodium hydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid sodium hydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid sodium hydrate can be used for coronary artery disease and neural system disease research.
Biochemical Assay Reagents   Bacterial   SOD  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
29
HY-W127774 EDTA hydrate sodium
EDTA (Ethylenediaminetetraacetic acid) hydrate sodium is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA hydrate sodium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA hydrate sodium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA hydrate sodium can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research.
Biochemical Assay Reagents   SOD   Bacterial  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
29
HY-Y0682A Ethylenediaminetetraacetic acid disodium dihydrate
Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research.
Environmental Pollutants   SOD   Bacterial   Biochemical Assay Reagents  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
29
HY-12216 Resmetirom
Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease  
25
HY-N0035 Arctigenin
Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions.
MMP   Influenza Virus   Autophagy   Apoptosis  
Metabolic or Endocrine Disease   Pancreatic Cancer   Viral Infection   Pain   Digestive System Inflammation   Lung Fibrosis  
17
HY-18341 L-Thyroxine
L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4).
Thyroid Hormone Receptor   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
15
HY-B0140 Aminophylline
Aminophylline is a competitive phosphodiesterase 3/4 (PDE3/4) inhibitor. Aminophylline also acts as an adenosine receptor antagonist. Aminophylline elevates intracellular cAMP levels via competitive inhibition of PDE3 and PDE4, antagonizes adenosine A1 receptor (ADORA1), regulates intracellular calcium signaling and synaptic vesicle cycling, upregulates the PPAR signaling pathway, and downregulates glutamatergic synaptic pathways simultaneously. Aminophylline can be used in research related to major depressive disorder, epilepsy, asthma, and chronic obstructive pulmonary disease (COPD).
Phosphodiesterase (PDE)   Adenosine Receptor   PPAR  
Depression   Epilepsy   Pulmonary Disease  
14
HY-P0059 Teriparatide
Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research.
PTHR   Thyroid Hormone Receptor  
Cancer  
12
HY-N0234 Bavachinin
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity..
Amyloid-β   PPAR   HIF/HIF Prolyl-Hydroxylase  
Digestive System Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Ovarian Cancer   Depression   Digestive System Inflammation   Alzheimer's Disease   Obesity  
10
HY-P7999 PPAR gamma Protein, Human (His)
PPAR gamma LBD Protein, Human (His) is a His-fused PPAR-gamma-LBD protein expressed by E. coli, approximately 32.6 kDa. PPAR gamma LBD Protein can be used in the ligand screening assays, western blotting, and ELISA, et al.

Species: Human; Source: E. coli

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR gamma

8
HY-N0010 Geniposidic acid
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis.
FXR   Sirtuin   TNF Receptor   Interleukin Related  
Metabolic or Endocrine Disease  
7
HY-14823 Sobetirome
Sobetirome (GC-1) is a thyroid hormone receptor β (TRβ)-specific agonist which bind selectively to TRβ-1 with an EC50 of 0.16 μM.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
7
HY-141513 NH-3
NH-3 is an orally active, reversible thyroid hormone receptor (THR) antagonist with an IC50 of 55 nM. NH-3, a derivative of the selective thyromi-metic GC-1, inhibits binding of thyroid hormones to their receptor and that inhibits cofactor recruitment. NH-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Thyroid Hormone Receptor  
Neurological, Eye or Ear Disease  
5
HY-N0401A (Z)-Ligustilide
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer.
Bacterial   Estrogen Receptor/ERR   FATP  
Infection   Metabolic or Endocrine Disease   Breast Cancer  
5
HY-P0119A Lixisenatide acetate
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.
GLP Receptor   Akt   MEK   Reactive Oxygen Species (ROS)   Apoptosis   MMP  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
4
HY-N2025 Oroxin A
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.
PPAR   Glycosidase  
Digestive System Disease   Breast Cancer   Depression   Digestive System Inflammation   Obesity  
4
HY-B0208 Methimazole
Methimazole (Thiamazole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Glioblastoma   Graves’ Disease  
4
HY-44134 Dimethyl 2-oxoglutarate
Dimethyl 2-oxoglutarate (Dimethyl α-ketoglutarate) is a cell-permeable derivative of 2-oxoglutarate and tricarboxylic acid cycle metabolite with antioxidant properties. Dimethyl 2-oxoglutarate inhibits Autophagy. Dimethyl 2-oxoglutarate prevents mitochondrial damage and reduces ROS production. Dimethyl 2-oxoglutarate alleviates Carbon tetrachloride (HY-Y0298)-induced liver fibrosis. Dimethyl-2-oxoglutaric acid can be used in the research of diseases such as Alzheimer's disease, diabetes, and cardiomyopathy.
Endogenous Metabolite   Drug Derivative   Autophagy   Mitochondrial Metabolism   Reactive Oxygen Species (ROS)  
Glucose Metabolism   Alzheimer's Disease   Cardiomyopathy   Hepatic Fibrosis  
4
HY-P70473 FGF-21 Protein, Human (His)
FGF-21 Proteinas influences glucose uptake in adipocytes by inducing SLC2A1/GLUT1 expression, particularly with KLB's presence. It plays a crucial role in systemic glucose homeostasis and insulin sensitivity, interacting directly with KLB through its C-terminus and engaging with FGFR4. The protein's molecular mechanisms involve a complex interplay, emphasizing its broad impact beyond localized effects. FGF-21 Protein, Human (His) is the recombinant human-derived FGF-21 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Cytokines and Growth Factors FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

4
HY-P7173 FGF-21 Protein, Mouse
FGF-21 Protein, Mouse emerges as a metabolic hormone involved in the regulation of glucose, lipid, bile acid, and phosphate metabolism.

Species: Mouse; Source: E. coli

Cytokines and Growth Factors FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

4
HY-N1029 Norathyriol
Norathyriol (Mangiferitin) is a natural metabolite of Mangifera. Norathyriol inhibits α-glucosidase in a noncompetitive manner with an IC50 of 3.12 μM. Norathyriol inhibits PPARα, PPARβ, and PPARγ with IC50s of 92.8 µM, 102.4 µM, and 153.5 µM, respectively. Antioxidant, anticancer, antimicrobial, anti-inflammatory, anti-bacterial activities.
Glycosidase   PPAR  
Cancer   Inflammation or Immune System Disease  
3
HY-N2181 Acetylshikonin
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC50=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD).
Cytochrome P450   Apoptosis   Bacterial   Autophagy  
Cancer   Neurological, Eye or Ear Disease   Digestive System Disease   Bacterial Infection   Digestive System Inflammation   Glucose Metabolism  
3
HY-B0346 Propylthiouracil
Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research.
Environmental Pollutants   Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
3
HY-116374 Glycolithocholic acid
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
Endogenous Metabolite  
Digestive System Disease   Digestive System Inflammation  
3
HY-108910 Chymotrypsin
Chymotrypsin (EC 3.4.21.1; Chymotrypsin A) is an orally effective inhibitor targeting molecules such as TLR4, NF-κB, MMP-1, TNF-α, IL-1β, and IL-6. Chymotrypsin downregulates the TLR4/NF-κB signaling pathway, inhibiting the release of inflammatory factors, reducing cell infiltration and tissue damage. It also reduces the expression of tumor cell adhesion molecules (such as CD44 and CD54) and can be specifically detected by fluorescent probes (such as NBD-3). Chymotrypsin has anti-inflammatory, hepatoprotective, joint damage-reducing, liver protection against lipotoxicity, and anti-tumor metastasis functions. It can be used in research on diseases such as rheumatoid arthritis, non-alcoholic fatty liver disease, and melanoma metastasis. Chymotrypsin can be used in studies of inflammation, edema, and expectoration.
Toll-like Receptor (TLR)   NF-κB   MMP  
Breast Cancer   Digestive System Inflammation   Gastric Disease   Metastatic Melanoma   Pharyngitis   Rheumatoid Arthritis  
3
HY-P72651 FGF-21 Protein, Mouse (HEK293, His)
FGF-21 Proteinas influences glucose uptake in adipocytes by inducing SLC2A1/GLUT1 expression, particularly with KLB's presence. It plays a crucial role in systemic glucose homeostasis and insulin sensitivity, interacting directly with KLB through its C-terminus and engaging with FGFR4. The protein's molecular mechanisms involve a complex interplay, emphasizing its broad impact beyond localized effects. FGF-21 Protein, Mouse (HEK293, His) is the recombinant mouse-derived FGF-21 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Mouse; Source: HEK293

Cytokines and Growth Factors FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

3
HY-P7012 FGF-21 Protein, Human
FGF-21 Protein, Human is an atypical member of the fibroblast growth factor (FGF) subfamily, acts as a metabolic regulator with pleiotropic effects.

Species: Human; Source: E. coli

Cytokines and Growth Factors FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

3
HY-109569 Vitamin K2
Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma.
Autophagy   Apoptosis   Interleukin Related  
Liver Cancer   Digestive System Inflammation   Acute Myeloid Leukemia   Osteoporosis   Ulcerative Colitis  
2
HY-N8599 Cichoriin
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC50 values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y14R (IC50 = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2.
Amylases   Glycosidase   Lipase   Dipeptidyl Peptidase   p38 MAPK   PPAR   P2Y Receptor   NOD-like Receptor (NLR)   SARS-CoV   Pyroptosis   GLUT   Angiotensin-converting Enzyme (ACE)   NF-κB  
Digestive System Disease   Viral Infection   Digestive System Inflammation   Obesity  
2
HY-N0546 Ligustroflavone
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
CaSR   RIP kinase   Mixed Lineage Kinase   TGF-beta/Smad  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Colorectal Cancer   Prostate Cancer   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis  
2
HY-N2014 Verbenalin
Verbenalin is an orally active terpenoid glycoside that can be extracted from the medicinal plant Verbena officinalis. Verbenalin has anti-inflammatory, antiviral, and neuroprotective effects. Verbenalin has a strong binding affinity to the nsp-12 protein of the SARS-CoV-2 virus. Verbenalin can be used in the research of inflammatory and nervous system diseases such as hepatitis and Alzheimer's disease.
SARS-CoV   Amyloid-β   Ferroptosis   Tau Protein   Caspase   Bcl-2 Family  
Inflammation or Immune System Disease   Viral Infection   Cardiovascular Disease   Alzheimer's Disease  
2
HY-P1136B TAT-Gap19
TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice.
Gap Junction Protein  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
2
HY-P1136C TAT-Gap19 TFA
TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice.
Gap Junction Protein  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
2
HY-N0912 Rehmannioside D
Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis.
Sirtuin   Apoptosis   MDM-2/p53   Reactive Oxygen Species (ROS)   Bcl-2 Family   Caspase  
Inflammation or Immune System Disease   Hepatic Fibrosis  
2
HY-114360 Taurohyodeoxycholic acid
Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula.
Endogenous Metabolite   COX   Interleukin Related   Glutathione Peroxidase   TNF Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Prostate Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
2
HY-B1773A Sodium propionate
Sodium propionate is an orally active short-chain fatty acid. Sodium propionate can be produced by intestinal bacteria from the metabolism of dietary fiber. Sodium propionate increases PPAR-γ, inhibits NF-κB activation, and reduces COX-2 expression and NO production. Sodium propionate also induces Apoptosis and Autophagy. Sodium propionate reduces HSV-1-induced keratitis. Sodium propionate has anticancer effects against glioblastoma. Sodium propionate exhibits neuroprotective, antioxidant, and anti-inflammatory activities. Sodium propionate can be used in the research of spinal cord injury and Alzheimer's disease.
Environmental Pollutants   Bacterial   PPAR   NO Synthase   Endogenous Metabolite   HSV   COX   Apoptosis   Autophagy   NF-κB  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Alzheimer's Disease   Obesity   Rheumatoid Arthritis  
2
HY-P99930 Efruxifermin
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis.

Species: Human

FGFR  
Digestive System Disease   Digestive System Inflammation  
2
HY-P7996 PPAR alpha Protein, Human (His)
PPAR alpha Protein, human (His), a member of the nuclear receptor family, is a transcription factor that regulates the expression of genes related to lipid metabolism in a ligand-dependent manner.

Species: Human; Source: E. coli

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR alpha

2
HY-P700468 GLP1R Protein, Human (HEK293, N-His, C-Myc)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

2
HY-P81160 GLP-1R Antibody
GLP-1R Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to GLP-1R.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

2
HY-Y1325E Sodium acetate trihydrate, United States Pharmacopeia (USP) Reference Standard
Sodium acetate trihydrate, United States Pharmacopeia (USP) Reference Standard (Sodium acetate trihydrate (Pharmaceutical primary standard, USP)) is a carboxylic acid and short-chain fatty acid (SCFAs). Sodium acetate trihydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Sodium acetate trihydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Sodium acetate trihydrate regulates energy metabolism. Sodium acetate trihydrate has anticancer activity against gastric cancer. Sodium acetate trihydrate induces writhing reaction and ulcerative colitis. Sodium acetate trihydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain.
Environmental Pollutants   Caspase   Reactive Oxygen Species (ROS)   Endogenous Metabolite   AMPK   Fungal   PPAR  
Gastric Cancer   Pain   Liver Disease   Colitis  
1
HY-W127601 Lard oil
Lard oil is an orally active biochemical reagent. Lard oil upregulates PERK, eIF2a, CHOP, OPN, TLR2, TLR4, TNF-α, and downregulates GRP78 and IRE1a. Lard oil induces responses such as body fat accumulation, elevated serum insulin levels, increased HOMA-IR, hepatic ectopic lipid deposition, hepatic endoplasmic reticulum stress, and hepatic inflammation. Lard oil can be used in studies related to diet-induced obesity, insulin resistance, and non-alcoholic fatty liver disease.
Biochemical Assay Reagents   PERK   Eukaryotic Initiation Factor (eIF)   Toll-like Receptor (TLR)   TNF Receptor   IRE1  
Insulin Resistance   Obesity  
1
HY-P1145 Glucagon-like peptide 1 (1-37), human
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.
GCGR  
Metabolic or Endocrine Disease  
1
HY-W018392S Mono-(2-ethylhexyl) phthalate-d4
Mono-(2-ethylhexyl) phthalate-d4 is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD).
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
1
HY-113064 Selenocystine
Selenocystine is a broad-spectrum anti-cancer agent. Selenocystine induces DNA damage in HepG2 cells, particularly in the form of DNA double strand breaks (DSBs). Selenocystine exhibits great promise as a therapeutic or adjuvant agent targeting DNA repair for cancer treatment.
Endogenous Metabolite  
Cancer  
1
HY-N0630 Shanzhiside methyl ester
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance.
GCGR  
Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation  
1
HY-137899 Dephospho-CoA
Dephospho-CoA is a key intermediate in the biosynthesis of coenzyme A (CoA), which is catalyzed to form CoA by GTP-dependent Dephospho-CoA kinase (DPCK). Dephospho-CoA completes the final synthetic step of CoA via phosphorylation and participates in energy metabolism and cellular signal transduction. Dephospho-CoA can be used in studies involving cancer (e.g., regulation of cell proliferation) and metabolic diseases (e.g., mitochondrial dysfunction).
Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
1
HY-114367 Delphinidin 3-rutinoside chloride
Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ETB receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes.
Endothelin Receptor   NO Synthase   Myosin   GLP Receptor  
Muscle Disease   Type 2 Diabetes  
1
HY-P1145A Glucagon-like peptide 1 (1-37), human TFA
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.
GCGR  
Metabolic or Endocrine Disease  
1
HY-N0723 Neomangiferin
Neomangiferin is an orally active natural flavonoid. Neomangiferin partially ameliorates non-alcoholic fatty liver disease (NAFLD) by regulating the expression of genes related to free fatty acid uptake and lipid oxidation. Neomangiferin exerts anti-colitis effects by inhibiting Th17/Treg cell differentiation. Neomangiferin exerts anti-aging and lifespan-extending effects by targeting upregulation of bas-1, which in turn activates the autophagy, IIS and MAPK pathways. Neomangiferin has the potential to prevent aseptic loosening of prostheses after total joint arthroplasty due to its significant anti-inflammatory and osteoclastogenesis-inhibiting effects.
Autophagy   p38 MAPK   TNF Receptor   Interleukin Related   PPAR  
Digestive System Disease   Colitis   Fatty Liver Disease   Osteoporosis  
1
HY-N1548 Prunasin
Prunasin is an orally active cyanogenic glucoside and the main metabolite of Amygdalin (HY-N0190). Prunasin can specifically inhibit rat DNA polymerase β (IC50: 98 μM). Prunasin has anti-inflammatory and anti-fibrotic activities. Prunasin can be used in the research of diseases such as liver fibrosis.
DNA/RNA Synthesis  
Inflammation or Immune System Disease  
1
HY-P3463 Beinaglutide
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).
GCGR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-N0732 Jolkinolide B
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
IAP   Akt   Caspase   NF-κB   TGF-beta/Smad   JAK   Bacterial   Apoptosis  
Cancer   Mycobacterium Tuberculosis Infection   Asthma   Fatty Liver Disease  
1
HY-W011121 2-Oleoylglycerol
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC50 value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .
GPR119   NF-κB   TGF-beta/Smad   GLP Receptor  
Metabolic or Endocrine Disease  
1
HY-W018161 Hexadecanedioic acid
Hexadecanedioic acid (Thapsic acid) is an orally active metabolite produced by B. uniformis. Hexadecanedioic acid inhibits IRE1α-XBP1s-mediated flipogenesis and ferroptosis. Hexadecanedioic acid downregulates XBP1 and Hrd1 expression, activates the Nrf2/SLC7A11/GPX4 pathway. Hexadecanedioic acid can be used for the research of metabolic-associated fatty liver disease.
IRE1   Ferroptosis   Keap1-Nrf2   Glutathione Peroxidase  
Metabolic or Endocrine Disease  
1
HY-W250122 Glutamic acid sodium salt
Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders.
Biochemical Assay Reagents   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   Apoptosis   HSP   Bcl-2 Family  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-143712 Allolithocholic acid
Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.
Drug Metabolite   G protein-coupled Bile Acid Receptor 1   ROR  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-Y1325H Sodium acetate trihydrate, meets analytical specification of Ph. Eur. BP USP FCC E262, ≤0.00002% Al
Sodium acetate trihydrate, meets analytical specification of Ph. Eur. BP USP FCC E262, ≤0.00002% Al is a carboxylic acid and short-chain fatty acid (SCFAs). Sodium acetate trihydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Sodium acetate trihydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Sodium acetate trihydrate regulates energy metabolism. Sodium acetate trihydrate has anticancer activity against gastric cancer. Sodium acetate trihydrate induces writhing reaction and ulcerative colitis. Sodium acetate trihydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain.
Environmental Pollutants   Caspase   Reactive Oxygen Species (ROS)   Endogenous Metabolite   AMPK   Fungal   PPAR  
Gastric Cancer   Pain   Liver Disease   Colitis  
1
HY-P72206 GLP1R Protein, Mouse (His-SUMO)
GLP1R protein, a G-protein coupled receptor, binds to GLP-1, activating adenylyl cyclase and increasing intracellular cAMP levels. This interaction regulates insulin secretion and maintains glucose homeostasis. GLP1R can also form dimers with GIPR, suggesting complex regulatory mechanisms and interactions with other receptors. GLP1R Protein, Mouse (His-SUMO) is the recombinant mouse-derived GLP1R protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

Species: Mouse; Source: E. coli

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

1
HY-P702843 PPAR alpha Protein, Mouse (His)
PPAR alpha Protein, Mouse (His), a member of the nuclear receptor family, is a transcription factor that regulates the expression of genes related to lipid metabolism in a ligand-dependent manner.

Species: Mouse; Source: E. coli

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR alpha

1
HY-P80871 PPAR alpha Antibody
PPAR alpha Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PPAR alpha.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

1
HY-P80436 PPAR gamma Antibody (YA122)
PPAR gamma Antibody (YA122) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PPAR gamma.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

1
HY-P87712 PPAR-γ Antibody (YA7397)
PPAR-γ Antibody (YA7397) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to PPAR-γ.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

1
HY-P11274 Zenagamtide
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   GCGR   Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-P10873 ST-CY14
ST-CY14 is an inhibitor for Nur77-PPARγ interaction with an EC50 of 3.15 μM, that binds to Nur77 (Kd=32 nM), blocks Nur77 from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models.
Nuclear Hormone Receptor 4A/NR4A   Mitochondrial Metabolism  
/
HY-14728S Deutaleglitazar
Deutaleglitazar (Aleglitazar-d2) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ).
PPAR  
/
HY-W777365 Ethylenediaminetetraacetic acid-13C4
Ethylenediaminetetraacetic acid-13C4 (EDTA-13C4) is the 13C-labeled Ethylenediaminetetraacetic acid (HY-Y0682). Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research.
Isotope-Labeled Compounds   Biochemical Assay Reagents   SOD   Bacterial  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P992066 Anti-Mouse DDR2 Antibody (DAB0065)
Anti-Mouse DDR2 Antibody (DAB0065) is a mAb that specifically targets mouse discoidin domain receptor DDR2 without cross-reacting with DDR1. Anti-Mouse DDR2 Antibody (DAB0065) binds to the extracellular domain of native mouse DDR2, induces endocytosis and lysosomal degradation of DDR2, and this process is independent of collagen binding. Anti-Mouse DDR2 Antibody (DAB0065) exhibits significant therapeutic effects in both the unilateral ureteral obstruction (UUO) mouse model of renal fibrosis and the bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, effectively downregulating the mRNA expression of type I collagen Col1a1 and fibronectin Fn1. Anti-Mouse DDR2 Antibody (DAB0065) can be humanized and has the potential to be developed as a targeted agent for diseases such as idiopathic pulmonary fibrosis and renal fibrosis.

Species: Mouse

Discoidin Domain Receptor  
Lung Fibrosis  
/
HY-P11880 LY3324954
LY3324954 is a long-acting, highly selective glucagon receptor (GCGR) agonist. LY3324954 stimulates cAMP production via the hepatic GCGR signaling pathway and induces acute blood glucose elevation, while promoting FGF21 expression in the liver and plasma. LY3324954 reduces body weight and abdominal fat mass, increases energy expenditure, and effectively improves lipid homeostasis, insulin sensitivity, and glucose intolerance. LY3324954 can be used in obesity-related research.
GCGR  
Obesity  
/
HY-P5345 KLA peptide
KLA peptide is a naturally occurring Antibiotic peptide that is nontoxic outside of cells but is toxic when it enters into the interior of targeted cells. KLA peptide can induce cell Apoptosis by disrupting mitochondrial membranes and activating Caspase. MG1-KLA, formed by the coupling of KLA peptide with MG1, can selectively induce apoptosis in pro-inflammatory microglia. KLA peptide can be used for the research of liver fibrosis. KLA peptide can be used for the research of neonatal hypoxic-ischemic encephalopathy.
Apoptosis   Antibiotic   Caspase   Mitochondrial Metabolism  
Infection   Cerebrovascular Disease   Hepatic Fibrosis  
/
HY-172439S Simedeutirom
Simedeutirom is the agonist for thyroid hormone beta receptor (THRβ) and can be used for researchs of metabolic diseases, such as obesity and diabetes mellitus.
Isotope-Labeled Compounds   Thyroid Hormone Receptor  
Metabolic or Endocrine Disease  
/
HY-N17383 Ligusticum cycloprolactam
Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease.
Toll-like Receptor (TLR)   NF-κB   Collagen   Interleukin Related   Cadherin   NOD-like Receptor (NLR)   TGF-β Receptor   FXR   Apoptosis  
Digestive System Disease   CNS Infection   Digestive System Inflammation   Hyperuricemia  
/
HY-B0637S1 Bezafibrate-d4
Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
Isotope-Labeled Compounds   PPAR  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P11590 WGYRGFYC
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer.
EGFR  
Breast Cancer  
/
HY-W750488 Glycolithocholic acid-d5
Glycolithocholic acid-d5 (Lithocholylglycine-d5) is the deuterium labeled Glycolithocholic acid (HY-116374). Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-N0234R Bavachinin (Standard)
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity..
Reference Standards   Amyloid-β   PPAR   HIF/HIF Prolyl-Hydroxylase  
Inflammation or Immune System Disease   Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-181896S PPARγ agonist-23
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC50 of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis.
PPAR  
Digestive System Disease   Digestive System Inflammation  
/
HY-N10640 Alismanol M
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC50 value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis.
FXR  
Inflammation or Immune System Disease  
/
HY-N16066 Candidusin A
Candidusin A (CHNQD-0803) (Compound 4) is a AMPK activator with a KD of 47.28 nM. Candidusin A can be isolated from marine fungus Aspergillus candidus. Candidusin A has cytotoxic activity and induces apoptosis in human prostate cancer cells (22Rv1, PC-3 and LNCaP cells). Candidusin A reduces adipogenesis genes expression and fat deposition, negatively regulates the NF-κB-TNFα inflammatory axis to suppress inflammation, and ameliorates liver injury and fibrosis. Candidusin A can be used for non-alcoholic steatohepatitis (NASH) research.

Source: Aspergillus candidus

AMPK   Apoptosis   NF-κB   TNF Receptor  
Inflammation or Immune System Disease  
/
HY-145581S Mitiperstat-d3
Mitiperstat-d3 (AZD4831-d3) is the deuterated -labeled Mitiperstat (HY-145581).Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease.
Isotope-Labeled Compounds   Glutathione Peroxidase   Cytochrome P450  
Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease   Chronic Obstructive Pulmonary Disease  
/
HY-163263S HSD17B13-IN-80-d3
HSD17B13-IN-80-d3 (179) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
17β-HSD  
Metabolic or Endocrine Disease  
/
HY-P11042 TE-8105
TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-127166R Colchiceine (Standard)
Colchiceine (Standard) is the analytical standard of Colchiceine. This product is intended for research and analytical applications. Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis.
Microtubule/Tubulin   Reference Standards  
Inflammation or Immune System Disease  
/
HY-P11826 T2 peptide-1
T2 peptide-1 is a linear peptide derived from Lumican degradation. T2 peptide-1 exhibits activity against endometrial adhesion progression and ability to inhibit the Lumican−Collagen I interaction. T2 peptide-1 can be used for the research of liver fibrosis.
Collagen  
Hepatic Fibrosis  
/
HY-W018161S Hexadecanedioic acid-d28
Hexadecanedioic acid-d28 is the deuterium labeled Hexadecanedioic acid (HY-W018161). Hexadecanedioic acid (Thapsic acid) is an orally active metabolite produced by B. uniformis. Hexadecanedioic acid inhibits IRE1α-XBP1s-mediated flipogenesis and ferroptosis. Hexadecanedioic acid downregulates XBP1 and Hrd1 expression, activates the Nrf2/SLC7A11/GPX4 pathway. Hexadecanedioic acid can be used for the research of metabolic-associated fatty liver disease.
Isotope-Labeled Compounds   IRE1   Ferroptosis   Keap1-Nrf2   Glutathione Peroxidase  
Metabolic or Endocrine Disease  
/
HY-Y0682S2 Ethylenediaminetetraacetic acid-d4
Ethylenediaminetetraacetic acid-d4 (EDTA-d4) is the deuterium labeled Ethylenediaminetetraacetic acid (HY-Y0682). Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research.
Isotope-Labeled Compounds   SOD   Biochemical Assay Reagents   Bacterial   Environmental Pollutants  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-D3234 Cy-AP
Cy-AP is a hypoxia-sensitive near-infrared Fluorescent probe (emission wavelength: 725 nm). Cy-AP exhibits no fluorescence under normoxic microenvironments, while under hypoxic microenvironments, its azo group is reduced, releasing strong near-infrared fluorescence with an emission at 725 nm. Cy-AP enables visualization of intracellular hypoxic status through multiple imaging modalities.
Fluorescent Dye  
/
HY-Y0319G1 Magnesium acetate tetrahydrate, for molecular biology
Magnesium acetate tetrahydrate, for molecular biology is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate, for molecular biology activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Magnesium acetate tetrahydrate, for molecular biology exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Magnesium acetate tetrahydrate, for molecular biology regulates energy metabolism. Magnesium acetate tetrahydrate, for molecular biology has anticancer activity against gastric cancer. Magnesium acetate tetrahydrate, for molecular biology induces writhing reaction and ulcerative colitis. Magnesium acetate tetrahydrate, for molecular biology can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain.
Biochemical Assay Reagents  
/
HY-N17992 Gypenoside UL5
Gypenoside UL5 (Compound UL5) is a dammarane-type triterpene saponin found in Gynostemma pentaphyllum. Gypenoside UL5 shows liver injury-inhibiting, anti-inflammatory and antioxidant properties. Gypenoside UL5 can be used for the research of hepatitis, fatty liver, and liver fibrosis.
Others  
Inflammation or Immune System Disease   Liver Disease   Fatty Liver Disease  
/
HY-B1588S Carbenoxolone-d4
Carbenoxolone-d4 is the d4 labeled Carbenoxolone (HY-B1588). Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis.
Isotope-Labeled Compounds   Amyloid-β   Gap Junction Protein  
Alzheimer's Disease   Hepatic Fibrosis  
/
HY-P11881 IUB288
IUB288 is a stable and long-acting glucagon-modified peptide, as well as a highly selective Glucagon Receptor agonist. IUB288 stimulates the production of cAMP, increases the expression levels of FGF21 in plasma and liver, regulates bile acid metabolism, and inhibits the expression of hepatic HMGCR. IUB288 improves hypercholesterolemia, enhances insulin sensitivity, increases core body temperature, boosts energy expenditure, suppresses food intake, and can also induce hyperglycemia and glucose intolerance. IUB288 is applicable to the research of diet-induced obesity, type 2 diabetes, and obesity-related glucose intolerance.
GCGR   GLP Receptor   FGFR   HMG-CoA Reductase (HMGCR)  
Type 2 Diabetes   Obesity  
/
HY-N4215 11(α)-Methoxysaikosaponin F
11(α)-Methoxysaikosaponin F is a triterpenoid saponin isolated from Bupleurum marginatum Wall.ex DC(ZYCH) which is a promising therapeutic for liver fibrosis. 11(α)-Methoxysaikosaponin F has an IC50 of 387.7 nM with viability of hepatic stellate cells-T6 (HSCs-T6). Triterpenoid saponins have numerous targets, important network positions, and strong inhibitory activity.
Others  
Inflammation or Immune System Disease  
/
HY-160266 THR-β agonist 7
THR-β agonist-1 (Example 2) is a THR-β agonist, with EC50 values of 52 nM and 1017 nM for THR-β and THR-α, respectively.
Thyroid Hormone Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-17356G Fenofibrate (GMP)
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
Cytochrome P450   Autophagy   PPAR  
Blood or Cardio-cerebrovascular Disease  
/
HY-12216S Resmetirom-13C3,15N
Resmetirom-13C3,15N (MGL-3196-13C3,15N) is the 13C- and 15N-labeled Resmetirom (HY-12216). Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis.
Isotope-Labeled Compounds   Thyroid Hormone Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-153476 GIP/GLP-1 dual receptor agonist-1
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
GCGR   GLP Receptor  
Digestive System Disease   Digestive System Inflammation  
/
HY-P11818 GIPR/GLP-1R/GCGR agonist-1
GIPR/GLP-1R/GCGR agonist-1 (compound 686) is a triple receptor agonist with activity at GLP-1R, GIPR, and GCGR. GIPR/GLP-1R/GCGR agonist-1 functionally modulates target receptors to drive cAMP generation. GIPR/GLP-1R/GCGR agonist-1 can be used for the research of type 2 diabetes mellitus, obesity, nonalcoholic fatty liver disease.
GLP Receptor   GCGR  
Digestive System Disease   Digestive System Inflammation   Type 2 Diabetes   Obesity  
/
HY-P11262 GUB021794
GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC50 value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC50 value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes.
GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-P992000 F8-IL-4
F8-IL-4 is an immune cytokine targeting IL-4. F8-IL-4 specifically delivers IL-4 to inflammatory sites via binding to targets expressed on neovascular vessels. F8-IL-4 alleviates collagen-induced arthritis in mice by regulating T cell subsets and macrophage polarization. When combined with Dexamethasone (HY-14648), F8-IL-4 produces a synergistic and long-lasting therapeutic effect, and prevents arthritis recurrence after drug withdrawal by maintaining anti-inflammatory cell phenotypes and cytokine profiles. F8-IL-4 can be used in the research of collagen-induced arthritis.

Species: Human

Interleukin Related  
Autoimmune Disease  
/
HY-168943 PLGA nanoparticles, 100nm
PLGA nanoparticles, 100nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 100nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 100nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 100nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research.
Biochemical Assay Reagents  
Cancer  
/
HY-163259S HSD17B13-IN-62-d3
HSD17B13-IN-62-d3 (176) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
17β-HSD  
Metabolic or Endocrine Disease  
/
HY-B0287S Clofibrate-d4
Clofibrate-d4 is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.
PPAR  
Metabolic or Endocrine Disease  
/
HY-P992508 SPX-101
SPX-101 (SX001) is a humanized monoclonal antibody targeting CLDN18.2. CLDN18.2 is only transiently expressed in the differentiated epithelial cells of the gastric mucosa and is hardly found in healthy tissues, thus having an extremely wide therapeutic window. SPX-101 can be used for the study of solid tumors.

Species: Human

Claudin  
Cancer  
/
HY-168943A PLGA nanoparticles, 200nm
PLGA nanoparticles, 200nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 200nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 200nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 200nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research.
Biochemical Assay Reagents  
Cancer  
/
HY-B0149S3 Tranexamic acid-13C2,15N
Tranexamic acid-13C2,15N (Cyclocapron-13C2,15N) is the 13C2 and 15N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury.
Isotope-Labeled Compounds  
Inflammation or Immune System Disease  
/
HY-109089S Epeleuton-d5
Epeleuton-d5 (15(S)-HEPE-d5 ethyl ester) is deuterium labeled Epeleuton. Epeleuton is a second-generation synthetic N-3 fatty acid derivative with activity in patients with non-alcoholic fatty liver disease, although it did not reach the primary endpoints of alanine aminotransferase and liver stiffness, but it can significantly reduce triglycerides, glycated hemoglobin, plasma glucose and inflammatory markers.
Isotope-Labeled Compounds  
/
HY-N16637 (3R,5R)-3,5-Dihydroxy-1,7-bis(3,4-dihydroxyphenyl)heptane 3-O-β-D-glucopyranoside
(3R,5R)-3,5-Dihydroxy-1,7-bis(3,4-dihydroxyphenyl)heptane 3-O-β-D-glucopyranoside is a diarylheptanol glycoside compound isolated from Tacca plantaginea. (3R,5R)-3,5-Dihydroxy-1,7-bis(3,4-dihydroxyphenyl)heptane 3-O-β-D-glucopyranoside significantly inhibit TNF-α-induced NF-κB transcriptional activity (IC50 = 9.4 μM). (3R,5R)-3,5-Dihydroxy-1,7-bis(3,4-dihydroxyphenyl)heptane 3-O-β-D-glucopyranoside significantly activates PPAR transcriptional activity (EC50 = 9.9 μM) and has a specific activating effect on PPAR β(δ) (EC50 = 23.1 μM). (3R,5R)-3,5-Dihydroxy-1,7-bis(3,4-dihydroxyphenyl)heptane 3-O-β-D-glucopyranoside is non-toxic to cells at the tested concentration. (3R,5R)-3,5-Dihydroxy-1,7-bis(3,4-dihydroxyphenyl)heptane 3-O-β-D-glucopyranoside can be used for research on inflammatory conditions.
NF-κB   PPAR  
Inflammation or Immune System Disease  
/
HY-168943B PLGA nanoparticles, 500nm
PLGA nanoparticles, 500nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 500nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 500nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 500nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research.
Biochemical Assay Reagents  
Cancer  
/
HY-114558S1 Resmethrin-d6
Resmethrin-d6 (Benzofuroline-d6) is the deuterium labeled Resmethrin (HY-114558). Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC50s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
Isotope-Labeled Compounds   Environmental Pollutants   Insecticide  
Inflammation or Immune System Disease  
/
HY-N16478 Echihumiline
Echihumiline is an alkaloid targeting hepatic cytochrome P450 enzymes (CYP450). Echihumiline induces DNA cross-linking and oxidative stress in hepatocytes, leading to liver necrosis and fibrosis. Echihumiline is promising for research of liver diseases.
Cytochrome P450  
Metabolic or Endocrine Disease  
/
HY-P11348 TG-MMP-Lys
TG-MMP-Lys is an MMP-sensitive crosslinking peptide. TG-MMP-Lys is promising for research of fibrotic diseases (e.g., liver fibrosis).
MMP  
Cancer  
/
HY-P3436A WLSEAGPVVTVRALRGTGSW TFA
WLSEAGPVVTVRALRGTGSW TFA is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW TFA can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure).
Exosomes  
Blood or Cardio-cerebrovascular Disease  
/
HY-159771 FAP6-19
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
FAP  
Cancer  
/
HY-P992339 cT84.66
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies.

Species: Human

Radionuclide-Drug Conjugates (RDCs)  
Colorectal Cancer  
/
HY-P11589 PIISVYWK
PIISVYWK is an orally active PPARγ Inhibitor, heme oxygenase-1 Activator, and Nrf2 Activator. PIISVYWK mediates activity via the HO-1/Nrf2 pathway, ameliorates oxidative stress, reduces inflammation, and mediates anti-obesity activity. PIISVYWK can be used for the research of obesity.
PPAR   Reactive Oxygen Species (ROS)   Keap1-Nrf2  
Obesity  
/
HY-P10133 PRDX3(103-112) SO3 modified, human
PRDX3(103-112) SO3 modified, human is a marker of ferroptosis, and can be used for liver diseases study.
Ferroptosis  
Metabolic or Endocrine Disease  
/
HY-P11549 pPB peptide
pPB peptide is a cyclic peptide targeting platelet-derived growth factor receptor β (PDGFRβ). Derived from natural platelet-derived growth factor (PDGF), pPB peptide contains arginine and isoleucine as key receptor-binding residues. pPB peptide specifically binds to PDGFRβ, which is highly expressed on the surface of activated hepatic stellate cells (HSC). pPB peptide can be used in studies related to liver fibrosis, liver cirrhosis, and tumor-specific drug delivery.
PDGFR  
Cancer   Lung Fibrosis  
/
HY-172836S GLP-1 receptor agonist 17-d3
GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases.
GCGR  
Blood or Cardio-cerebrovascular Disease  
/
HY-P11235 Berobenatide
Berobenatide (PF-08653944; MET-097) is a GLP-1R agonist that exerts functional regulation of GLP-1R biased toward the Gs protein signaling pathway. Berobenatide induces weight loss in diet-induced obese mice. Berobenatide can be used in obesity-related research.
GLP Receptor  
Lipid Metabolism  
/
HY-W701772 2-Oleoylglycerol-d5
2-Oleoylglycerol-d5 (2-OG-d5) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC50 value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .
Isotope-Labeled Compounds   NF-κB   TGF-beta/Smad   GPR119   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-P10220 NOTA-COG1410
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with 68Gallium (68Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Radionuclide-Drug Conjugates (RDCs)   TREM receptor  
/
HY-P11207 NLS-CPP
NLS-CPP is a nuclear localization signal (NLS)-cell-penetrating peptide, which contains the NLS of OCT6. NLS-CPP facilitates nuclear delivery. NLS-CPP can be used for chronic inflammatory diseases s research, such as metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA).
Others  
Inflammation or Immune System Disease  
/
HY-N21699 Uralione E
Uralione E is a naturally occurring polycyclic polyprenylated acylphloroglucinol (PPAP). Uralione E exhibits a protective effect against corticosterone (HY-B1618)-induced damage in PC12 cells. In a free fatty acid (FFA)-induced L02 cell model, Uralione E dose-dependently reduces intracellular lipid accumulation, downregulates the expression of FASN and CD36, and upregulates the expression of ACOX1 and PPARα. Uralione E can be used in studies related to neuronal cell damage, lipid metabolism, and non-alcoholic steatohepatitis.
Fatty Acid Synthase (FASN)   PPAR  
Digestive System Disease   Digestive System Inflammation  
/
HY-N144101 SARS-CoV MPro-IN-2
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 Mpro with an IC50 value of 72.07 nM. The main protease (Mpro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19.
SARS-CoV  
/
HY-P11827 C11 peptide-1
C11 peptide-1 is an antifibrotic agent that binds directly to Collagen I. C11 peptide-1 physically disrupts Collagen I interaction with Lumican. C11 peptide-1 reduces inflammatory infiltration and inhibits the ERK1/2 and Smad2/3 signaling pathways. C11 peptide-1 can be used for the research of liver fibrosis.
Collagen   ERK   TGF-beta/Smad  
Hepatic Fibrosis  
/
HY-P6177 SGP8
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH).
Dipeptidyl Peptidase  
Inflammation or Immune System Disease  
/
HY-P11208 mNLS-CPP-WSTF
mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-113806 (±)-Trolline
(±)-Trolline ((±)-Oleracein E), an isoquinoline alkaloid, exhibits antibacterial activity against respiratory bacteria and antiviral activity against influenza virus A and B. (±)-Trolline significantly induces HSC apoptosis. (±)-Trolline can be used for the research of liver fibrosis.
Bacterial   Influenza Virus   Apoptosis  
Inflammation or Immune System Disease  
/
HY-N0630R Shanzhiside methyl ester (Standard)
Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance.
Reference Standards   GCGR  
Neurological, Eye or Ear Disease  
/
HY-P2032 Cyclochlorotine
Cyclochlorotine is a mycotoxin that can be extracted from the yellow rice infectant Penicillium islandicum Sopp. Cyclochlorotine promotes glycogenolysis, inhibits glycogen synthesis, affects fat synthesis and protein synthesis in liver cells. Cyclochlorotine exhibits chronic toxicity in liver that induces liver fibrosis and cirrhosis in mouse models. Cyclochlorotine exhibits carcinogenicity.

Source: Penicillium islandicum

Endogenous Metabolite  
Cancer   Infection  
/
HY-127166 Colchiceine
Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis.
Microtubule/Tubulin  
Inflammation or Immune System Disease  
/
HY-117110 Arginylproline
Arginylproline (H-Arg-Pro-OH) is a dipeptide consisted of arginine and proline. Arginylproline reduces intracellular triglyceride (TG) levels stimulated by Oleic acid (HY-N1446), through the peptide transporter 1 (PepT1) pathway.
Proton Pump  
Metabolic or Endocrine Disease  
/
HY-P0119S Lixisenatide (Leu-13C6,15N) TFA
Lixisenatide (Leu-13C6,15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.
Isotope-Labeled Compounds   GLP Receptor   Akt   MEK   Apoptosis   Reactive Oxygen Species (ROS)   MMP  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-168943C PLGA nanoparticles, 1μm
PLGA nanoparticles, 1μm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 1μm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 1μm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 1μm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research.
Biochemical Assay Reagents  
Cancer  
/
HY-P0014AS Liraglutide-d8 tetraTFA
Liraglutide-d8 tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-N11924 Foenumoside B
Foenumoside B is a triterpene saponin isolated from Lysimachia foenum-graecum. Foenumoside B activates AMPK signaling, inhibits PPARγ-induced adipogenesis, and shifts lipid metabolism toward lipolysis. Foenumoside B can be used in the study of obesity and obesity-related metabolic diseases.
AMPK   PPAR  
Metabolic or Endocrine Disease  
/
HY-P1624S Teduglutide-Ala(13C3,15N) sodium
Teduglutide-Ala(13C3,15N) (ALX-0600-Ala(13C3,15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Isotope-Labeled Compounds   FXR   Nuclear Hormone Receptor 4A/NR4A  
/
HY-N2025R Oroxin A (Standard)
Oroxin A (Standard) is the analytical standard of Oroxin A. This product is intended for research and analytical applications. Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.
Reference Standards   PPAR   Glycosidase  
Cancer   Metabolic or Endocrine Disease  
/
HY-107737R 1,2-DLPC (Standard)
1,2-DLPC (Standard) is the analytical standard of 1,2-DLPC (HY-107737). This product is intended for research and analytical applications. 1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breaKdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells.
Reference Standards   Liposome   Apoptosis   TNF Receptor   PPAR  
/
HY-B0760S1 Fenofibric acid-13C8
Fenofibric acid-13C8 (FNF acid-13C8) is 13C labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.
Isotope-Labeled Compounds   PPAR   COX  
Metabolic or Endocrine Disease  
/
HY-B0637S2 Bezafibrate-13C6
Bezafibrate-13C6 (BM15075-13C6) is 13C labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
Isotope-Labeled Compounds   PPAR  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P990989 Efmedaglutide alfa
HY-P990989 is an GLP-1 receptor-targeting Fusion Protein.
GLP Receptor  
Inflammation or Immune System Disease  
/
HY-P11291A NNC0165-1273 TFA
NNC0165-1273 TFA is a selective NPY Y2 receptor agonist with a Ki of 2 nM and an EC50 of 5.0 nM. NNC0165-1273 TFA blocks Ghrelin-induced cFos expression. NNC0165-1273 TFA reduces nocturnal food intake, attenuates feeding behavior, induces early satiety, and causes dose-dependent decreases in body weight and fat mass in diet-induced obese mice. When used in combination with Semaglutide (HY-114118), NNC0165-1273 TFA reduces preference for high-fat diet, promotes body weight loss, and produces sustained weight loss effects in diet-induced obese rats. NNC0165-1273 TFA can be used in studies related to diet-induced obesity.
Neuropeptide Y Receptor  
Obesity  
/
HY-P11271 Ribupatide
Ribupatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research.
Insulin Receptor   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-N9333 Wistin
Wistin, isolated from Caragana sinica roots, is a PPARα and PPARγ agonist.
PPAR  
Cancer   Metabolic or Endocrine Disease  
/
HY-N13201 12-Deoxyphorbol 13-palmitate
12-Deoxyphorbol 13-palmitate is a traditional Chinese medicine monomer with antitumor activity that can be isolated from the root of Euphorbia fischeriana. 12-Deoxyphorbol 13-palmitate induces gastric cancer cell cycle arrest and apoptosis by regulating key cell cycle regulators such as cyclin B、cyclin A and CDC2. In addition, 12-Deoxyphorbol 13-palmitate can significantly weaken APOL2–SERCA2–PERK–HES1 signaling and slow liver fibrosis by targeting APOL2.
Apoptosis   CDK  
Cancer  
/
HY-P4116A pH-Low Insertion Peptide TFA
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors.
Others  
Cancer   Metabolic or Endocrine Disease  
/
HY-14806S Teneligliptin-d8
Teneligliptin-d8 is a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor.
Dipeptidyl Peptidase  
Blood or Cardio-cerebrovascular Disease  
/
HY-17386S Rosiglitazone-d3
Rosiglitazone-d3 is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3.
Isotope-Labeled Compounds   PPAR   TRP Channel   Autophagy   Ferroptosis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P10957 Imapextide
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research.
GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-P1624S1 Teduglutide-Leu(13C6,15N) sodium
Teduglutide-Leu(13C6,15N) (ALX-0600-Leu(13C6,15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Isotope-Labeled Compounds   FXR   Nuclear Hormone Receptor 4A/NR4A  
/
HY-P990990 Efsubaglutide alfa
Efsubaglutide alfa is a long-acting humanised GLP-1 receptor agonist. Efsubaglutide alfa binds specifically to the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon release, and promoting β-cell proliferation and increased β-cell mass. Efsubaglutide alfa improves glucose tolerance, increases pancreatic insulin content, and enhances β-cell secretory responses in isolated human islets. Efsubaglutide alfa reduces liver steatosis, lowers NAFLD Activity Scores, improves perisinusoidal collagen features, reduces serum ALT and AST levels, improves fasting glucose and triglyceride levels, and reduces body weight, liver weight and liver-to-body weight ratio. Efsubaglutide alfa can be used for the research of type 2 diabetes. Efsubaglutide alfa can be used for the research of metabolic dysfunction-associated steatohepatitis.

Species: Human

GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Type 2 Diabetes  
/
HY-113513 5-HEPE
5-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). 5(S)-HEPE increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

Source: Caenorhabditis elegan

Others  
Cancer  
/
HY-13956R Pioglitazone (Standard)
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research.
Reference Standards   PPAR   Ferroptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-123115 Leucrose
Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active Sucrose (HY-B1779) isomer naturally found in pollen and honey. Leucrose promotes phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokinesas (TNFα, and IL-1β), increases M2 macrophage polarization and suppresses DSS (HY-116282C)-induced colitis. Leucrose suppresses hepatic triglyceride accumulation, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice. Leucrose is slowly hydrolyzed into glucose and fructose by α-glucosidase and acts as as a sugar substitute in diet.
JAK   STAT   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N2452 Cochinchinenin C
Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions.
GLP Receptor  
Helicobacter Pylori Infection   Platelet Disease   Type 2 Diabetes  
/
HY-116374R Glycolithocholic acid (Standard)
Glycolithocholic acid (Standard) is the analytical standard of Glycolithocholic acid. This product is intended for research and analytical applications. Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
Endogenous Metabolite   Reference Standards  
Inflammation or Immune System Disease  
/
HY-N0035R Arctigenin (Standard)
Arctigenin (Standard) is the analytical standard of Arctigenin. This product is intended for research and analytical applications. Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions.
Reference Standards   MMP   Influenza Virus   Autophagy   Apoptosis  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P11208C mNLS-CPP-WSTF TFA
mNLS-CPP-WSTF TFA is the trifluoroacetate salt of mNLS-CPP-WSTF (HY-P11208). mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-P0014S2 Liraglutide-13C6,15N TFA
Liraglutide-13C6,15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds  
/
HY-N0046 Notoginsenoside Fe
Notoginsenoside Fe (Notoginseng triterpenes; Ginsenoside Mb) is a saponin with anti-obesity and anti-neuroblastoma activities. Notoginsenoside Fe can be isolated from leaves of Panax notoginseng. Notoginsenoside Fe specifically activates paraventricular nucleus neurons in the hypothalamus, effectively reducing body weight, improving fasting blood glucose and protecting liver function by decreasing food intake, increasing resting metabolic rate and enhancing energy expenditure. Notoginsenoside Fe also inhibits the c-Src signaling pathway, blocks the proliferation and viability of human neuroblastoma cells, while improving mitochondrial dysfunction and alleviating apoptosis. Notoginsenoside Fe can be used in studies related to diet-induced obesity and neuroblastoma.
Apoptosis   Src  
Glioblastoma   Obesity  
/
HY-P2435 Bz-Nle-Lys-Arg-Arg-AMC
Bz-Nle-Lys-Arg-Arg-AMC can be used for protease activity assay. In 0.1mL Tris-HCl buffer (50 mM, pH 7.8), Bz-Nle-Lys-Arg-Arg-AMC was hydrolyzed, and the release rate of AMC was observed.
Others  
/
HY-142026 Vitisin A
Vitisin A ((+)-Vitisin A) is an orally active natural product with multiple pharmacological activities including anti-inflammatory, anti-tumor, anti-oxidant, anti-pathogenic microorganism, hypoglycemic and lipid-regulating, anti-osteoporotic, neuroprotective and cardiovascular protective effects. Vitisin A exhibits inhibitory effects on human AChE and MAO-B with IC50 values of 1.29 µM and 4.94 µM, respectively. Vitisin A inhibits the ERK, MAPK, NF-κB, STAT1, HMGCR and TRAF6 pathways, downregulates the related phosphorylation and protein expression, while activates the Nrf2/HO-1 pathway and upregulates p21 expression. Vitisin A induces tumor cell apoptosis and cell cycle arrest, inhibits adipogenesis and lipid accumulation, while alleviates oxidative stress, suppresses inflammatory responses, blocks hepatic fibrosis, Cuproptosis and cholesterol synthesis, and increases the expression levels of central BDNF and TrkB. Vitisin A can be used in the research of tumors, infectious diseases, metabolic diseases, bone and joint diseases, liver diseases, skin injuries, as well as neurodegenerative and cognitive dysfunction-related diseases.
Caspase   ERK   NF-κB   Influenza Virus   PAK   LDLR   PPAR   PCSK9   Androgen Receptor   Keap1-Nrf2   Monoamine Oxidase   Cholinesterase (ChE)   IKK   Wnt   β-catenin   Reactive Oxygen Species (ROS)   Apoptosis   Cuproptosis  
Cancer   Infection   Metabolic or Endocrine Disease   Neurodegenerative Disease   Antioxidant Agent  
/
HY-B0637S Bezafibrate-d6
Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
PPAR  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-153476A GIP/GLP-1 dual receptor agonist-1 sodium
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
GLP Receptor   GCGR  
Digestive System Disease   Digestive System Inflammation  
/
HY-P5311 Albiglutide
Albiglutide is a long acting GLP-1 receptor agonist. Albiglutide is a recombinant fusion protein consisting of two copies of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36), modified with a glycine substituted for the naturally occurring alanine at position 8 in order to augment resistance to DPP-4. Albiglutide can be used for research of Type 2 diabetes.

Species: Human

GLP Receptor  
Type 2 Diabetes  
/
HY-N9182 Zeaxanthin dipalmitate
Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with p2X7 receptor (Kd=81.2 nM) and adiponectin receptor 1 (AdipoR1; Kd=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP).
Adiponectin Receptor   P2X Receptor   Autophagy  
Inflammation or Immune System Disease  
/
HY-114118S1 Semaglutide-d8 tetraTFA
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-145632A Pemvidutide TFA
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research.
GLP Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-D2415 BODIPY-FL staurosporine
BODIPY-FL staurosporine (Compound 8a) is a fluorescence probe based on staurosporine, exhibiting high specificity towards tyrosine kinases (TK) and tyrosine kinase-like (TKL) family kinases. BODIPY-FL staurosporine has the potential to develop binding assays for kinases that are not recommended for use with Kinase Tracer 236, such as PIM3, CDC42BPG, MAP2K7, TXK, and SIK3. BODIPY-FL staurosporine can be a powerful tool for analyzing kinase selectivity in kinase drug discovery.
Fluorescent Dye  
/
HY-Y0850U3 PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization)
PVA (Polyvinyl alcohol) (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) is a water-soluble, biodegradable, biocompatible and non-immunogenic polymer. PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) causes no irritation to rabbit eyes, no skin sensitization in guinea pigs, promotes the proliferation of human skin keratinocytes, and reduces the loss of corneal endothelial cells. The LD50 of PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) in rats and dogs is greater than 10 g/kg. PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) is hardly absorbed by the digestive system, causes no adverse effects upon long-term oral administration, and shows no mutagenicity or carcinogenicity. However, repeated intravenous or portal vein injection of PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) may induce pathological changes such as glomerular lesions, anemia, hypertension or liver fibrosis in rats or dogs. Crosslinked nanofibers prepared by modifying PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) can be used in studies related to wound dressings and other applications.
Biochemical Assay Reagents  
/
HY-116374S Glycolithocholic acid-d4
Glycolithocholic acid-d4 is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P3436 WLSEAGPVVTVRALRGTGSW
WLSEAGPVVTVRALRGTGSW is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure).
Exosomes  
Heart Disease  
/
HY-P2310A Defensin HNP-1 human TFA
Defensin HNP-1 human TFA is a type of human neutrophil peptide (HNPs). Defensin HNP-1 human TFA possesses immunomodulatory functions and can delay the apoptosis of neutrophils. Defensin HNP-1 human TFA inhibits DNA/RNA/protein synthesis and interferes with metabolic pathways, thus exhibiting broad antibacterial activity. Defensin HNP-1 human TFA has direct inactivation effects on HIV, HSV-1, HSV-2, CMV, influenza virus, etc. Defensin HNP-1 human TFA has antileishmanial activity. Defensin HNP-1 human TFA is involved in endothelial cell dysfunction during the early development of atherosclerosis.
Bacterial   Parasite   Apoptosis   HIV   HSV   CMV   TNF Receptor   Interleukin Related   NOD-like Receptor (NLR)   DNA/RNA Synthesis   Influenza Virus  
Infection   Blood or Cardio-cerebrovascular Disease  
/
HY-N9459 2-Amino-2-deoxyglucose hydrochloride
2-Amino-2-deoxyglucose hydrochloride (D-Glucosamine Hydrochloride) is a glucose analog that is specifically recognized and transported by the cell membrane GLUT1. 2-Amino-2-deoxyglucose hydrochloride acts as a tumor-targeting ligand and a guiding molecule for the synthesis of prodrug conjugates, thus delivering drugs precisely to tumor cells. 2-Amino-2-deoxyglucose hydrochloride is applicable to diagnostic imaging and therapeutic efficacy monitoring of solid tumors and various cancers (e.g., breast cancer, glioblastoma). 2-Amino-2-deoxyglucose hydrochloride also helps bacteria resist lysozyme digestion by integrating into the non-N-acetylated residues of Streptococcus pneumoniae peptidoglycan. 2-Amino-2-deoxyglucose hydrochloride is used in studies on tumor metabolism and the exploration of bacterial drug resistance mechanisms.

Source: Shrimp, crab and other crustaceans

GLUT  
Breast Cancer   Bacterial Infection   Glioblastoma  
/
HY-P99428 Aldafermin
Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH).
Others  
Metabolic or Endocrine Disease  
/
HY-P11237 Enicepatide
Enicepatide (CT-388) is a cAMP signal-biased dual GLP-1R and GIPR agonist peptide, with an EC50 value of 0.087 nM for GLP-1R cAMP, and an EC50 value of 2.47 nM for GIPR cAMP. Enicepatide activates the cAMP signaling pathway, while recruiting only minimal amounts of β-arrestin-2 at both targets and reducing receptor internalization levels. Enicepatide improves glycemic control, reduces body weight, suppresses appetite, and ameliorates the pathological conditions of metabolic dysfunction-associated steatohepatitis. Enicepatide can be used in the research of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis.
GCGR   Insulin Receptor  
Digestive System Disease   Digestive System Inflammation   Type 2 Diabetes   Obesity  
/
HY-78197 3,5-Dimethylisoxazole-4-boronic acid pinacol ester
3,5-Dimethylisoxazole-4-boronic acid pinacol ester is a drug intermediate that can be used for the synthesis of bromodomain inhibitors.
Drug Intermediate  
/
HY-P990013 Gulgafafusp alfa
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R.

Species: Human

GCGR  
Metabolic or Endocrine Disease  
/
HY-N6911A 18α-Licorice-saponin H2
18α-Glycyrrhizic acid (18α-GA; Isoglycyrrhizinic acid; 18α-Glycyrrhizic acid) is a derivative of glycyrrhizic acid with oral activity. 18α-Glycyrrhizic acid exhibits antioxidant, anti-inflammatory, hepatoprotective and cardioprotective activities. 18α-Glycyrrhizic acid protects against ethanol-induced alcoholic liver disease in rats by upregulating the expression levels of SOD, GSH, PPAR-α and CPT-1. 18α-Glycyrrhizic acid shows cytotoxicity against T lymphocytes and inhibits HIV-1 replication in these cells. 18α-Glycyrrhizic acid alleviates oxidative stress by reducing the levels of ROS, Nrf2, HO-1 and p-P65, and alleviates pyroptosis by downregulating the expression levels of NLRP3, GSDMD-N, P20 and c-IL-1β. 18α-Glycyrrhizic acid inhibits autophagy, colonic fibrosis and myocardial fibrosis, and regulates intestinal barrier integrity. 18α-Glycyrrhizic acid can be used in research related to alcoholic liver disease, HIV-1 infection, hepatotoxicity, acute liver failure, inflammatory bowel disease and myocardial fibrosis.
SOD   PPAR   Carnitine Palmitoyltransferase (CPT)   HIV   Reactive Oxygen Species (ROS)   Keap1-Nrf2   Heme Oxygenase (HO)   NOD-like Receptor (NLR)   Interleukin Related   Pyroptosis   Autophagy   NF-κB   TNF Receptor  
Inflammation or Immune System Disease  
/
HY-B0760S Fenofibric acid-d6
Fenofibric acid-d6 (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.
PPAR   COX  
Metabolic or Endocrine Disease  
/
HY-128421 Tridecanedioic acid
Tridecanedioic acid (Brassylic Acid) is a long-chain fatty acid and an endogenous serum metabolite. Tridecanedioic acid is positively correlated with the intestinal genus Tuzzerella in non-alcoholic steatohepatitis (NASH) mice fed a MCD diet. Tridecanedioic acid accumulates at high levels in Brassica napus germplasm tolerant to Plutella xylostella (diamondback moth), thereby participating in plant defense. Tridecanedioic acid can be used in studies related to Plutella xylostella infestation.
Endogenous Metabolite   Insecticide  
Digestive System Disease   Plant Infection   Digestive System Inflammation  
/
HY-114118S Semaglutide-d8
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK   GLP Receptor   Apoptosis   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-145632 Pemvidutide
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research.
GLP Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-N4124 Poricoic acid B
Poricoic acid B is a triterpenoid compound that can be isolated from Poria cocos. Poricoic acid B inhibits intracellular lipid accumulation and reduces the levels of hepatocyte injury markers. Poricoic acid B inhibits the production of NO, TNF-α, IL-1β and IL-6, thereby exerting anti-inflammatory activity. Poricoic acid B can be used in the research of metabolic dysfunction-associated fatty liver disease and inflammatory diseases.
NO Synthase   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Fatty Liver Disease  
/
HY-153563 MMP-7-IN-2
MMP-7-IN-2 is a potent and selective inhibitor of MMP7 with an IC50 value of 16 nM. MMP-7-IN-2 can be used for the research of diseases such as cancer and fibrosis.
MMP  
/
HY-N9914R D-Psicose (Standard)
D-Psicose (Standard) is the analytical standard of D-Psicose (HY-N9914). This product is intended for research and analytical applications. D-psicose is an orally active rare sugar. D-psicose inhibits p38-MAPK phosphorylation and MCP-1 expression. D-psicose inhibits the AGEs/RAGE/NF-κB pathway. D-psicose protects pancreatic β-islets, improves hyperglycemia and high-fat diet-induced non-alcoholic fatty liver disease.
Reference Standards   p38 MAPK   NF-κB  
Metabolic or Endocrine Disease  
/
HY-P1348 GLP-1 moiety from Dulaglutide
GLP-1 moiety from Dulaglutide ([Gly8,36,Glu22]-GLP-1 (7-37)) is a 31-amino acid fragment derived from Dulaglutide (HY-P0120). GLP-1 moiety from Dulaglutide is a DPP-4-modified GLP-1 analog carrying the [Gly8,36,Glu22] sequence mutation, which acts as a GLP-1 receptor agonist. GLP-1 moiety from Dulaglutide covalently links to the human IgG4 Fc fragment and constitutes a part of the dulaglutide recombinant fusion protein. GLP-1 moiety from Dulaglutide exhibits glucose-dependent insulinotropic activity. GLP-1 moiety from Dulaglutide can be used in research related to type 2 diabetes.
GCGR   Dipeptidyl Peptidase   GLP Receptor  
Type 2 Diabetes  
/
HY-N6022 Byakangelicin
Byakangelicin, one of the active compounds found in the roots of Angelica gigas, can serve as a modulator to improve brain accumulation of diverse active compounds (Umb, Cur, and Dox) and enhance therapeutic effects. Byakangelicin is likely to increase the expression of all PXR target genes (such as MDR1) and induce a wide range of agent-agent interactions. Byakangelicin can inhibit the effects of sex hormones, it may increase the catabolism of endogenous hormones.
Others  
Cancer   Metabolic or Endocrine Disease  
/
HY-P2310 Defensin HNP-1 human
Defensin HNP-1 human is a type of human neutrophil peptide (HNPs). Defensin HNP-1 human possesses immunomodulatory functions and can delay the apoptosis of neutrophils. Defensin HNP-1 human inhibits DNA/RNA/protein synthesis and interferes with metabolic pathways, thus exhibiting broad antibacterial activity. Defensin HNP-1 human has direct inactivation effects on HIV, HSV-1, HSV-2, CMV, influenza virus, etc. Defensin HNP-1 human has antileishmanial activity. Defensin HNP-1 human is involved in endothelial cell dysfunction during the early development of atherosclerosis.
Bacterial   Parasite   Apoptosis   HIV   HSV   CMV   TNF Receptor   NOD-like Receptor (NLR)   DNA/RNA Synthesis   Influenza Virus  
Infection   Blood or Cardio-cerebrovascular Disease  
/
HY-P99697 Leronlimab
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.

Species: Human

CCR   HIV  
Cancer   Infection  
/
HY-P1144 Oxyntomodulin (bovine, porcine)
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist.
GCGR  
Metabolic or Endocrine Disease  
/
HY-P10302A GLP-1R/GIPR agonist-1 (soduim)
GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC50 of 0.57 nM for GLP-1R and an EC50 of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis.
GLP Receptor  
Digestive System Disease   Autoimmune Disease   Digestive System Inflammation   Obesity  
/
HY-P0014S1 Liraglutide-13C5,15N tetraTFA
Liraglutide-13C6,15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds   GCGR   GLP Receptor  
/
HY-124081 N-Oleoyl-L-serine
N-Oleoyl-L-Serine is an endogenous amide of long-chain fatty acids with ethanolamine (N-acyl amides). N-Oleoyl-L-Serine is a lipid regulator of bone remodeling and stimulates osteoclast apoptosis. N-Oleoyl-L-Serine can be used for antiosteoporotic drug discovery development.
Apoptosis  
Metabolic or Endocrine Disease  
/
HY-P4116 pH-Low Insertion Peptide
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors.
Others  
Cancer   Metabolic or Endocrine Disease  
/
HY-P0165 Taspoglutide
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
GCGR  
Metabolic or Endocrine Disease  
/
HY-114118CP Semaglutide (crude)
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-Z11724 Semaglutide Main Chain (9-37)
Semaglutide Main Chain (9-37) is a peptide starting material in the synthesis of semaglutide (HY-114118).
Drug Derivative  
Metabolic or Endocrine Disease  
/
HY-P99614 Fazpilodemab
Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD).

Species: Human

FGFR  
Metabolic or Endocrine Disease  
/
HY-P990964 Efimosfermin alfa
Efimosfermin alfa is a genetically engineered FGF21 variant. Efimosfermin alfa exerts its function by activating the FGFR1c/β-Klotho complex. Efimosfermin alfa is applicable to researches on metabolic dysfunction-associated steatohepatitis, obesity and mild hypertriglyceridemia.

Species: Human

FGFR  
Inflammation or Immune System Disease   Obesity   Hypertriglyceridemia  
/
HY-D1555 Cyanine7 DBCO
Cyanine7 DBCO (Cy7 DBCO) is a near-infrared fluorescent dye and an efficient bio-orthogonal quencher. Cyanine7 DBCO is formed by covalent connection of the near-infrared fluorescent dye Cy7 and the dibenzocyclooctyne (DBCO) functional group. After reacting with N3-Cy5-COOH, the fluorescence of Cy5 decreases by 90% within 90 minutes, and rapid signal attenuation can be observed within 2-5 minutes. Cyanine7 DBCO can be used for the study of deep tissue imaging and receptor-targeted therapeutic strategies.
Fluorescent Dye  
/
HY-W018004 L-Homocitrulline
L-Homocitrulline is a carbamoylated derivative amino acid and a structural analog of L-citrulline. L-Homocitrulline serves not only as an intermediate in polypeptide synthesis but also converts into a variety of cyclic derivatives under enzymatic or acidic conditions. The level of L-Homocitrulline is significantly elevated in the serum of patients with non-alcoholic fatty liver disease (NAFLD), with high diagnostic accuracy. L-Homocitrulline also exists in patients with related diseases such as hypercitrullinemia. L-Homocitrulline is a key biomarker for monitoring abnormal liver metabolism and is widely used in NAFLD research.
Amino Acid Derivatives   Endogenous Metabolite  
Digestive System Disease   Digestive System Inflammation  
/
HY-45894 tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is an intermediate in the synthesis of the glucagon-like peptide 1 receptor (GLP-1R) agonist Semaglutide (HY-114118). tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu exhibits a strong binding affinity to albumin and can be used to modify SN38 prodrugs to improve tumor distribution.
GLP Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
/
HY-114118S3 Semaglutide-13C6,15N TFA
Semaglutide-13C6,15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK   GLP Receptor   Apoptosis   Bcl-2 Family  
Metabolic or Endocrine Disease  
/
HY-P10739 WYRGRL
WYRGRL is a selective, high-affinity collagen type II-binding peptide with a IC50 of 140 nM. Collagen type II is the most abundant and specific structural protein in the extracellular matrix of articular cartilage. WYRGRL can precisely target small-molecule compounds such as Dexamethasone (HY-14648) and nanocarrier-engineered exosomes to cartilage, significantly enhancing their therapeutic effects on osteoarthritis.
Exosomes   Collagen  
Inflammation or Immune System Disease   Osteoarthritis  
/
HY-P991219 Anti-IL11RA Antibody (X209)
Anti-IL11RA Antibody (X209) (EnX209) is a human-derived IgG4, κ-type antibody inhibitor targeting IL11RA, with a KD of 6 nM. Anti-IL11RA Antibody (X209) blocks the IL11RA signaling pathway, inhibits ERK-dependent activation, and reduces the activation level of ERK1/2. Anti-IL11RA Antibody (X209) exerts a protective effect against fibrosis. Anti-IL11RA Antibody (X209) is applicable to studies related to liver fibrosis, cardiac fibrosis and other related conditions. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003).

Species: Human

Interleukin Related   ERK   MMP  
Inflammation or Immune System Disease  
/
HY-12557 γ-Glutamylvaline
γ‑Glutamylvaline (γ-Glu-Val) is a calcium‑sensing receptor (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1 and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation.
Endogenous Metabolite   CaSR   Wnt   TNF Receptor   Interleukin Related   PPAR   β-catenin  
Inflammation or Immune System Disease  
/
HY-N15721 Tryptophan-cholic acid
Tryptophan-cholic acid (Trp-CA) is a microbial amino acid-conjugated bile acid that acts as an endogenous ligand and agonist (EC50=9.6 μM) for the orphan G protein-coupled receptor (GPCR) MRGPRE (Mas-related G protein-coupled receptor family member E). Tryptophan-cholic acid is orally effective but has poor oral absorption and does not cross the blood-brain barrier. Tryptophan-cholic acid promotes the secretion of glucagon-like peptide GLP-1, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid improves glucose tolerance, promotes insulin secretion, and alleviates high-fat diet-induced hepatic steatosis without causing pruritus side effects. Tryptophan-cholic acid is primarily used in research on type 2 diabetes (T2D).
Orphan GPCR   GLP Receptor  
Type 2 Diabetes  
/
HY-Y0319G Magnesium acetate tetrahydrate
Magnesium acetate tetrahydrate is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Magnesium acetate tetrahydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Magnesium acetate tetrahydrate regulates energy metabolism. Magnesium acetate tetrahydrate has anticancer activity against gastric cancer. Magnesium acetate tetrahydrate induces writhing reaction and ulcerative colitis. Magnesium acetate tetrahydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain.
Endogenous Metabolite   AMPK   Reactive Oxygen Species (ROS)   Caspase   Fungal   PPAR  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-126995 Glycohyodeoxycholic acid
Glycohyodeoxycholic acid is a glycine-conjugated bile acid and also a metabolite of Hyodeoxycholic acid (HY-N0169). The serum level of Glycohyodeoxycholic acid is negatively correlated with the severity of non-alcoholic fatty liver disease. Glycohyodeoxycholic acid can be used in research related to non-alcoholic fatty liver disease.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P991049 Atrosimab
Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis.

Species: Human

TNF Receptor  
Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis   Fatty Liver Disease  
/
HY-W011927 4,4'-Sulfonyldiphenol
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
Estrogen Receptor/ERR   Histone Methyltransferase   Thyroid Hormone Receptor   PI3K   Akt   mTOR   Androgen Receptor   Drug Derivative  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease  
/
HY-59291 Levacetylleucine
Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention.
Amino Acid Derivatives  
Neurodegenerative Disease   CNS Infection   Traumatic Brain Injury  
/
HY-P99143 Anti-Mouse NK1.1 Antibody (PK136)
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH).

Species: Mouse

Neurokinin Receptor   NF-κB   STAT  
Digestive System Disease   Digestive System Inflammation  
/
HY-P11274A Zenagamtide sodium
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   Insulin Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-Y1325I Sodium acetate trihydrate, 99.5%
Sodium acetate trihydrate, 99.5% is a carboxylic acid and short-chain fatty acid (SCFAs). Sodium acetate trihydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Sodium acetate trihydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Sodium acetate trihydrate regulates energy metabolism. Sodium acetate trihydrate has anticancer activity against gastric cancer. Sodium acetate trihydrate induces writhing reaction and ulcerative colitis. Sodium acetate trihydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain.
Fungal   PPAR   Caspase   Reactive Oxygen Species (ROS)   Endogenous Metabolite   AMPK  
Gastric Cancer   Pain   Liver Disease   Colitis  
/
HY-P702572 PPAR gamma Protein, Human (P.pastoris, His)
The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human (P.pastoris, His) is the recombinant human-derived PPAR gamma protein, expressed by P. pastoris , with N-6*His labeled tag.

Species: Human; Source: P. pastoris

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR gamma

/
HY-P701092 FGF-21 Protein, Human (181a.a)
FGF-21 Protein, Human (181a.a), Human is an atypical member of the fibroblast growth factor (FGF) subfamily, acts as a metabolic regulator with pleiotropic effects.

Species: Human; Source: E. coli

Cytokines and Growth Factors FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

/
HY-P704244 PPARD Protein, Human (His)
PPARD protein is a ligand-activated transcription factor that critically mediates energy metabolism in adipose tissue. As a receptor, it selectively binds peroxisome proliferators, including hypolipidemic drugs and fatty acids, and preferentially binds polyunsaturated substances. PPARD Protein, Human (His) is the recombinant human-derived PPARD protein, expressed by E. coli, with N-6*His labeled tag.

Species: Human; Source: E. coli

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR-delta

/
HY-P70352 GLP1R Protein, Human (HEK293, Fc)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, Fc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P72650 FGF-21 Protein, Cynomolgus (HEK293, His)
FGF-21 is a metabolic regulator and a potential anti-diabetic agent. FGF-21 regulates energy balance and glucose and lipid homeostasis through a heterodimeric receptor complex comprising FGFR1 and 尾-klotho. FGF-21 can also signal through FGFR2 and FGFR3. FGF-21 can be used for research of obesity, NASH, NAFLD, and type 2 diabetes mellitus. FGF-21 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived FGF-21 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Cynomolgus; Source: HEK293

Cytokines and Growth Factors FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

/
HY-P705437 PPAR gamma Protein, Mouse (His)
PPAR gamma is a regulator of adipocyte differentiation and glucose homeostasis, belonging to nuclear receptor protein families. PPAR gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. PPAR gamma Protein, Mouse (His) is expressed by E. coli and carries a N-terminal 10*His tag.

Species: Mouse; Source: E. coli

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR gamma

/
HY-P7S0363 PPARD Protein, Human (HEK293, His)
PPARD protein is a ligand-activated transcription factor that critically mediates energy metabolism in adipose tissue. As a receptor, it selectively binds peroxisome proliferators, including hypolipidemic drugs and fatty acids, and preferentially binds polyunsaturated substances. PPARD Protein, Human (HEK293, His) is the recombinant human-derived PPARD protein, expressed by HEK293, with C-6*His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR-delta

/
HY-P701336 PPAR gamma Protein, Human
The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human is the recombinant human-derived PPAR gamma protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR gamma

/
HY-P78442 FGF-21 Protein, Human (HEK293, mFc-Avi)
FGF-21 Proteinas, pivotal in promoting glucose uptake in adipocytes, induces SLC2A1/GLUT1 expression, not affecting SLC2A4/GLUT4, contingent on KLB.It significantly regulates systemic glucose homeostasis and insulin sensitivity, with direct KLB interaction via its C-terminus.Engagement with FGFR4 adds complexity to its molecular mechanisms, highlighting its role in orchestrating cellular responses beyond localized effects.FGF-21 Protein, Human (HEK293, mFc-Avi) is the recombinant human-derived FGF-21 protein, expressed by HEK293 , with N-mFc, N-Avi labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

/
HY-P73701 PPAR gamma Protein, Human (sf9, His-GST)
The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human (sf9, His-GST) is the recombinant human-derived PPAR gamma protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Species: Human; Source: Sf9 insect cells

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR gamma

/
HY-P704635 GLP1R Protein, Human (HEK293, His)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, His) is the recombinant human-derived GLP1R protein, expressed by HEK293, with C-His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P705021 FGF-21 Protein, Human (Biotinylated, HEK293, His-Avi)
FGF-21 Proteinas, pivotal in promoting glucose uptake in adipocytes, induces SLC2A1/GLUT1 expression, not affecting SLC2A4/GLUT4, contingent on KLB. It significantly regulates systemic glucose homeostasis and insulin sensitivity, with direct KLB interaction via its C-terminus. Engagement with FGFR4 adds complexity to its molecular mechanisms, highlighting its role in orchestrating cellular responses beyond localized effects. FGF-21, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived FGF-21 protein, expressed by HEK293, with C-Avi;C-hFc labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Biotinylated Proteins FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

/
HY-P705301 GLP1R Protein, Human (Biotinylated, HEK293, His-Avi)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived GLP1R protein, expressed by HEK293, with N-Avi labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Biotinylated Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P75762 FGF-21 Protein, Hamster (HEK293, His)
FGF21 is a liver factor that signals through the FGF21 receptor in the paraventricular nucleus of the hypothalamus to regulate monosaccharide intake and preference for sweets. FGF21 promotes the progression of non-small cell lung cancer by activating the SIRT1/PI3K/AKT signaling pathway. FGF21 plays an important role in embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF-21 Protein, Hamster (HEK293, His) is the recombinant FGF-21 protein, expressed by HEK293 , with C-His labeled tag.

Species: Others; Source: HEK293

Cytokines and Growth Factors FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

/
HY-P700719 FGF-21 Protein, Human (Biotinylated, HEK293, mFc-Avi)
FGF-21 Proteinas, pivotal in promoting glucose uptake in adipocytes, induces SLC2A1/GLUT1 expression, not affecting SLC2A4/GLUT4, contingent on KLB.It significantly regulates systemic glucose homeostasis and insulin sensitivity, with direct KLB interaction via its C-terminus.Engagement with FGFR4 adds complexity to its molecular mechanisms, highlighting its role in orchestrating cellular responses beyond localized effects.FGF-21 Protein, Human (Biotinylated, HEK293, mFc-Avi) is the recombinant human-derived FGF-21 protein, expressed by HEK293 , with N-Avi, N-mFc labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors Biotinylated Proteins FGF Family Fibroblast Growth Factor Fibroblast Growth Factor 21 (FGF-21)

/
HY-P706142 GLP1R Protein, Human (Cell-Free, His)
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (Cell-Free, His) is the recombinant human-derived GLP1R protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Species: Human; Source: E. coli Cell-free

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P705621 GLP1R Protein, Mouse (HEK293, His)
GLP1R protein, a G-protein coupled receptor, binds to GLP-1, activating adenylyl cyclase and increasing intracellular cAMP levels. This interaction regulates insulin secretion and maintains glucose homeostasis. GLP1R can also form dimers with GIPR, suggesting complex regulatory mechanisms and interactions with other receptors. GLP1R, Mouse (HEK293, His) is the recombinant mouse-derived GLP1R protein, expressed by HEK293, with labeled tag.

Species: Mouse; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P700275 PPAR gamma Protein, Human (C-His, solution)
The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human (C-His, solution) is the recombinant human-derived PPAR gamma protein, expressed by E. coli , with C-6*His labeled tag.

Species: Human; Source: E. coli

Receptor Proteins Nuclear Receptor Superfamily Peroxisome Proliferator-activated Receptor PPAR gamma

/
HY-P705973 GLP1R Protein, Cynomolgus (HEK293, His)

Species: Cynomolgus; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P705977 GLP1R Protein, Rat (HEK293, His)

Species: Rat; Source: HEK293

Receptor Proteins G-Protein-Coupled Receptors (GPCRs) Glucagon Receptor GLP-1 Receptor

/
HY-P80872 PPAR gamma Antibody
PPAR gamma Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PPAR gamma.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P83531 FGF21 Antibody (YA3276)
FGF21 Antibody (YA3276) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FGF21.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85457 PPAR gamma Antibody (YA5149)
PPAR gamma Antibody (YA5149) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PPAR gamma.

Host: Mouse; Reactivity: Human, Mouse, Rat, Bovine, Dog, Goat, Pig, Rabbit, Sheep

Monoclonal Antibodies Primary Antibodies

/
HY-P86449 PPAR alpha Antibody (YA6141)
PPAR alpha Antibody (YA6141) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PPAR alpha.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85753 PPAR Delta Antibody (YA5445)
PPAR Delta Antibody (YA5445) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PPAR Delta.

Host: Mouse; Reactivity: Human, Rat, Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-P810528 Semaglutide Antibody
Semaglutide Antibody is Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Semaglutide.

Host: Rabbit; Reactivity: Human

Polyclonal Antibodies Primary Antibodies

/
HY-P88048 PPAR Delta Antibody (YA7733)
PPAR Delta Antibody (YA7733) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PPAR Delta.

Host: Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-P811065 GLP-1 Receptor Antibody
GLP-1 Receptor Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to GLP-1 Receptor.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P85702 PPAR gamma Antibody (YA5394)
PPAR gamma Antibody (YA5394) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PPAR gamma.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P88048A PPAR Delta Antibody (YA7733)(PBS only)
PPAR Delta Antibody (YA7733) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PPAR Delta.

Host: Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-K0610 Sirius Red Staining Kit

MCE Sirius Red Staining Kit consists of hematoxylin staining solution and Sirius Red staining solution and is mainly used to observe abnormal collagen deposition or fibrosis in various pathological tissues. Under a conventional light microscope, collagen fibers in tissues such as the heart and blood vessels appear red. Under polarized light microscopy, this method is useful for the classification and evaluation of different types of fibrotic lesions.

Cell Biology Cell Analysis Staining Kit

/

Keywords

metabolic dysfunction-associated fatty liver disease | MAFLD | fatty liver disease | steatohepatitis | liver fibrosis | therapeutic targets | THR-β | GLP-1 receptor | PPAR | FGF21 | resmetirom | semaglutide | lanifibranor | pegozafermin | metabolic dysfunction | drug discovery